1. Home
  2. BLRX vs KRKR Comparison

BLRX vs KRKR Comparison

Compare BLRX & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • KRKR
  • Stock Information
  • Founded
  • BLRX 2003
  • KRKR 2010
  • Country
  • BLRX Israel
  • KRKR China
  • Employees
  • BLRX N/A
  • KRKR N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • KRKR Business Services
  • Sector
  • BLRX Health Care
  • KRKR Consumer Discretionary
  • Exchange
  • BLRX Nasdaq
  • KRKR Nasdaq
  • Market Cap
  • BLRX 12.1M
  • KRKR 11.7M
  • IPO Year
  • BLRX 2011
  • KRKR 2019
  • Fundamental
  • Price
  • BLRX $5.74
  • KRKR $5.90
  • Analyst Decision
  • BLRX Strong Buy
  • KRKR
  • Analyst Count
  • BLRX 2
  • KRKR 0
  • Target Price
  • BLRX $19.00
  • KRKR N/A
  • AVG Volume (30 Days)
  • BLRX 2.0M
  • KRKR 3.8K
  • Earning Date
  • BLRX 05-27-2025
  • KRKR 03-11-2025
  • Dividend Yield
  • BLRX N/A
  • KRKR N/A
  • EPS Growth
  • BLRX N/A
  • KRKR N/A
  • EPS
  • BLRX N/A
  • KRKR N/A
  • Revenue
  • BLRX $22,340,000.00
  • KRKR $31,657,328.00
  • Revenue This Year
  • BLRX N/A
  • KRKR $182.55
  • Revenue Next Year
  • BLRX N/A
  • KRKR N/A
  • P/E Ratio
  • BLRX N/A
  • KRKR N/A
  • Revenue Growth
  • BLRX 91.68
  • KRKR N/A
  • 52 Week Low
  • BLRX $2.30
  • KRKR $2.76
  • 52 Week High
  • BLRX $35.60
  • KRKR $12.99
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 73.10
  • KRKR 67.04
  • Support Level
  • BLRX $3.88
  • KRKR $5.68
  • Resistance Level
  • BLRX $7.77
  • KRKR $5.91
  • Average True Range (ATR)
  • BLRX 0.75
  • KRKR 0.08
  • MACD
  • BLRX 0.19
  • KRKR -0.06
  • Stochastic Oscillator
  • BLRX 56.81
  • KRKR 55.00

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About KRKR 36Kr Holdings Inc.

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.

Share on Social Networks: